Unit | Clinical Research

Participant in paediatric TB diagnostic trial, Bagamoyo, Tanzania

The aim of the Clinical Research Unit (CRU) is to design, conduct, analyse and report clinical research studies at Swiss TPH and partner institutions and to provide support for Swiss TPH scientists for clinical questions. The CRU has a focus on clinical trials in phase I to III.

Research

The CRU aims to strengthen high standard clinical research at Swiss TPH. The CRU conducts clinical research in the areas of malaria, febrile illnesses, tuberculosis, HIV/AIDS, neglected tropical diseases, and emerging non-communicable chronic diseases in low- and middle-income countries in collaboration with numerous partner institutes. Key CRU research areas are found under "Main CRU Activities".

Support

The members of the CRU, who have a wide range of expertise in clinical research, provide scientific support with regard to clinical and methodological aspects during the development of research proposals and protocols. The clinical support is part of the Project and Grant Service at Swiss TPH. All proposals and protocols for clinical trials are reviewed by the CRU. Observational clinical studies may also be reviewed if desired by the investigators.

Research Clinic at IHI, Kingani, Tanzania

Vanobberghen F et al. A decade of HIV care in rural Tanzania: trends in clinical outcomes and impact of clinic optimisation in an open, prospective cohort. PLoS One. 2017;12(7):e0180983. DOI: 10.1371/journal.pone.0180983

Letang E et al. Cohort profile: the Kilombero and Ulanga Antiretroviral Cohort (KIULARCO): a prospective HIV cohort in rural Tanzania. Swiss Med Wkly. 2017;147:w14485. DOI: 10.4414/smw.2017.14485

Muri L et al. Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania - an emerging public health concern. AIDS. 2017;31(1):61-70. DOI: 10.1097/QAD.0000000000001273

Erb S et al. Health care provider communication training in rural Tanzania empowers HIV-infected patients on antiretroviral therapy to discuss adherence problems. HIV Med. 2017(in press). DOI: 10.1111/hiv.12499

Boeree M.J et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017;17(1):39-49. DOI: 10.1016/S1473-3099(16)30274-2